---
title: "Amantadine - Postencephalitic parkinsonism"
sidebar: mydoc_sidebar
permalink: amantadinepostencephaliticparkinsonism.html
toc: false 
---

{% include image.html url="images/amantadinepostencephaliticparkinsonism.png" file="amantadinepostencephaliticparkinsonism.png" alt="amantadinepostencephaliticparkinsonism" %}

## Concepts

|------------|------|---------|
| Identifier | Name | Type    |
|------------|------|---------|
| MESH:D000547 | Amantadine | Drug |
| UniProt:P14416 | D(2) dopamine receptor | Protein |
| MESH:D004298 | Dopamine | ChemicalSubstance |
| GO:0061527 | Dopamine secretion, neurotransmission | BiologicalProcess |
| UBERON:0002038 | Substantia nigra | GrossAnatomicalStructure |
| MESH:D010301 | Postencephalitic parkinsonism | Disease |
|------------|------|---------|

## Relationships

|---------|-----------|---------|
| Subject | Predicate | Object  |
|---------|-----------|---------|
| Amantadine | INCREASES ACTIVITY OF | D(2) Dopamine Receptor |
| D(2) Dopamine Receptor | POSITIVELY CORRELATED WITH | Dopamine |
| Dopamine | POSITIVELY CORRELATED WITH | Dopamine Secretion, Neurotransmission |
| Dopamine Secretion, Neurotransmission | OCCURS IN | Substantia Nigra |
| Substantia Nigra | DISRUPTED BY | Postencephalitic Parkinsonism |
|---------|-----------|---------|

Reference: [https://go.drugbank.com/drugs/DB00915#mechanism-of-action](https://go.drugbank.com/drugs/DB00915#mechanism-of-action){:target="_blank"}